This peer-reviewed human study published in Nutrients characterizes, for the first time, the oral pharmacokinetics and endocrine effects of D-Pinitol in fasting healthy volunteers. The research demonstrates that D-Pinitol is efficiently absorbed after oral administration, exhibits an extended absorption phase, and presents a long plasma half-life exceeding five hours, supporting sustained physiological activity.
Importantly, the study shows that D-Pinitol significantly reduces circulating insulin levels while maintaining stable blood glucose, confirming its insulin-sparing metabolic profile in humans. These effects are mediated through coordinated endocrine actions, including increased glucagon and ghrelin secretion, without adverse effects on glucose homeostasis or pituitary hormone balance. No liver or kidney toxicity was observed.
This publication establishes D-Pinitol as a safe, orally active metabolic modulator with pancreatic protective potential, providing strong clinical support for Agelity® in metabolic health, insulin resistance prevention, and healthy aging applications.